The potential use of drugs to enhance cognition, emotion, and executive function has engendered controversy despite the fact that few such agents exist today. Here, I provide a context for discussions based on medical, regulatory, and ethical concerns that have been raised by the possibility that enhancers will emerge from current efforts to discover drugs for neuropsychiatric disorders.
Copyright © 2011 Elsevier Inc. All rights reserved.

Related Faculty

Photo of Steven Hyman

Steven Hyman is Director of the Stanley Center for Psychiatric Research at the Broad Institute, where his goal is to drive the genetics of schizophrenia to the point of diminishing returns with respect to biological information, with bipolar disorder following closely behind.

Search Menu